US 12,227,569 B2
Humanized antibodies with increased stability
Laurent Gauthier, Marseilles (FR); and Nicolas Schneider, Marseilles (FR)
Assigned to INNATE PHARMA, Marseilles (FR)
Filed by INNATE PHARMA, Marseilles (FR)
Filed on Jul. 15, 2021, as Appl. No. 17/376,314.
Application 16/398,472 is a division of application No. 15/125,216, granted, now 10,280,222, previously published as PCT/EP2015/055224, filed on Mar. 12, 2015.
Application 17/376,314 is a continuation of application No. 16/398,472, filed on Apr. 30, 2019, granted, now 11,066,470.
Claims priority of provisional application 61/953,035, filed on Mar. 14, 2014.
Prior Publication US 2021/0340254 A1, Nov. 4, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 9/00 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 47/02 (2006.01); A61K 47/12 (2006.01); A61K 47/26 (2006.01); C07K 16/30 (2006.01)
CPC C07K 16/2803 (2013.01) [A61K 39/39591 (2013.01); A61K 47/02 (2013.01); A61K 47/12 (2013.01); A61K 47/26 (2013.01); C07K 16/3061 (2013.01); A61K 9/0019 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/71 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/94 (2013.01)] 14 Claims
 
1. An expression vector comprising a recombinant nucleic acid encoding:
a) a VH region comprising SEQ ID NO: 31;
b) a VL region comprising SEQ ID NO: 25;
c) a VL region comprising SEQ ID NO: 26;
d) a VH region comprising SEQ ID NO: 14;
e) a VL region comprising SEQ ID NO: 9; or
f) a VH region comprising SEQ ID NO: 15.